Related Experiment Videos
The rationale for early management of chronic renal insufficiency
1University of Western Ontario, London Health Science Centre, 5339 Windermere Road, London, Ontario N6A 5A5, Canada.
Insights
Managing blood pressure and blood glucose, alongside ACE inhibitors and anemia treatment, can help slow chronic renal insufficiency (CRI) progression. Early intervention is key for optimal outcomes in delaying end-stage renal disease (ESRD).
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Endocrinology
Background:
- Hypertension is a significant risk factor for end-stage renal disease (ESRD).
- Chronic renal insufficiency (CRI) management requires addressing co-morbidities.
- Blood pressure (BP) control is crucial for patients with CRI.
Purpose of the Study:
- To review strategies for delaying renal disease progression.
- To evaluate the impact of BP management, glycemic control, ACE inhibitors, and anemia treatment on CRI outcomes.
Main Methods:
- Review of clinical studies on renoprotective strategies.
- Analysis of data on the effects of antihypertensive therapy, diabetes management, and epoetin treatment in CRI patients.
Main Results:
- Angiotensin-converting enzyme (ACE) inhibitors offer renoprotection beyond BP reduction, delaying ESRD.
- Intensive glycemic control in diabetes patients can reduce proteinuria and protect against ESRD.
- Epoetin treatment for renal anemia may reduce mortality and delay dialysis initiation in CRI patients.
Conclusions:
- BP control, glycemic management, ACE inhibitors, and anemia treatment show potential in slowing CRI progression.
- These interventions may improve patient outcomes and delay the need for dialysis.
- Early implementation of these strategies is likely to be most effective.
Abstract:
Several strategies are available to delay progression of renal disease and the development of associated co-morbidities. Hypertension is a strong independent risk factor for end-stage renal disease (ESRD) and there is consensus that blood pressure (BP) management is an important aspect of care in patients with chronic renal insufficiency (CRI). Clinical studies have shown that angiotensin-converting enzyme (ACE) inhibitors have renoprotective properties, independent of their antihypertensive effects, which can delay the onset of ESRD. Studies have also shown that intensive therapy of both type 1 and type 2 diabetes patients, to give near normal blood glucose concentrations, can reduce the incidence of progressive clinical proteinuria and may, therefore, protect against ESRD. Additionally, data are emerging that treatment of renal anaemia with epoetin can reduce mortality and delay the onset of dialysis in CRI patients, but these encouraging results need to be confirmed in large prospective studies. In conclusion, control of BP and hyperglycaemia, as well as use of ACE inhibitors and anaemia treatment, all have potential in delaying the progression of CRI or improving patient outcomes. If benefit is proven in future studies, these strategies will be most effective if implemented early in the course of CRI.